Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries

Gene Therapy

Volumn 11, Issue 17, 2004, Pages 1342-1350

  Wang, T ^a   Li, H ^a   Zhao, C ^a   Chen, C ^a   Li, J ^b   Chao, J ^c   Chao, L ^c   Xiao, X ^a,b   Wang, D W ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cardiovascular remodeling; Human tissue kallikrein; Hypertension; rAAV; Spontaneously hypertensive rat

Indexed keywords

ALBUMIN; COLLAGEN; COMPLEMENTARY DNA; KALLIKREIN; PARVOVIRUS VECTOR; HYBRID PROTEIN; MESSENGER RNA;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ATTENUATION; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DESIGN; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRANSGENE; URINALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; ANIMAL; CHEMISTRY; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; METHODOLOGY;

ADENO-ASSOCIATED VIRUS;

ANIMALS; CARDIOVASCULAR DISEASES; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HYPERTENSION; INJECTIONS, INTRAVENOUS; KALLIKREINS; KIDNEY; MALE; RATS; RATS, INBRED SHR; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSDUCTION, GENETIC;

EID: 4444239999     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302294     Document Type: Article

References (37)

1. Phillips MI. Is gene therapy for hypertension possible? Hypertension 1999; 33: 8-13.
2. Craig H et al. Current perspectives on the use of gene therapy for hypertension. Circ Res 2000; 87: 1118-1122.
3. Phillips MI. Gene therapy for hypertension: the preclinical data. Hypertension 2001; 38 (Part 2): 543-548.
4. Xiao X et al. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper virus. J Virol 1998; 72: 2224-2232.
5. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med 2000; 6: 599-602.
6. Monahan PE, Samulski RJ. AAV: is clinical success in the horizon? Gene Therapy 2000; 7: 24-30.
7. Margolius HS. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 1995; 26: 221-229.
8. Kitamura N et al. Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 1985; 260: 8610-8617.
9. Müller-Esterl W, Iwanga S, Nakaniski S. Kininogens revisited. Trends Biochem Sci 1986; 11: 336-339.
10. Nakaniski S, Substance P. Precursor and kininogen: their structures, gene organizations, and regulation. Physiol Rev 1987; 67: 1117-1142.
11. Adam A et al. Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin Chem 1985; 31: 423-426.
12. Elliot AH, Nuzum FR. The urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 1934; 18: 462-474.
13. Zinner SH et al. Stability of blood pressure rank and urinary kallikrein concentration in childhood. Circulation 1978; 58: 908-915.
14. Margolius HS. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Ann Rev Pharmacol Toxicol 1989; 29: 343-364.
15. Berry TD et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 13: 3-8.
16. Majima M et al. High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension 1993; 22: 705-714.
17. Favaro S et al. Renal kallikrein content of spontaneously hypertensive rats. Clin Sci 1975; 49: 69-71.
18. Mayfield R et al. Development of hypertension in rats made diabetic with streptozotocin is associated with decreased urinary kallikrein excretion. Diabetes 1985; 34: 22-28.
19. Sharma JN, Uma K, Noor AR, Rahman AR. Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996; 27: 55-63.
20. Katori M, Majima M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn Pharmacol 1996; 70: 95-128.
21. Mayfield RK, Margolius HS. Renal kallikrein-kinin system. Am J Nephrol 1983; 3: 145-155.
22. Chao J et al. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9: 21-31.
23. Chao J et al. Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 1998; 54: 1250-1260.
24. Dobrzynski E et al. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology 1999; 44: 57-65.
25. Murakami H et al. Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 1998; 53: 1305-1313.
26. Wolf WC et al. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 2000; 58: 730-739.
27. Yayama K et al. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31: 1104-1110.
28. Tolbert EM et al. Onset of glomerular hypertension with aging precedes injury in the spontaneously hypertensive rat. Am J Physiol Renal Physiol 2000; 278: F839-F846.
29. Francis SC et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics 2001; 21: 79-94.
30. Linz W, Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20 (Suppl 9): 583-590.
31. Yoshida H et al. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 2000; 35: 25-31.
32. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433-440.
33. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice with a rAAV vector. J Virol 1996; 70: 8098-8108.
34. Auricchio A et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
35. Xiong W, Chao J, Chao L. Muscle delivery of human kallikreingene reduces blood pressure in hypertensive rats. Hypertension 1995; 25: 715-719.
36. Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979; 27: 1131-1139.
37. Wang C et al. Adrenomedullin gene delivery attenuates renal damage and cardiac hypertrophy in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2001; 280: F964-F971.